Characterization of Bioceramics for Surgical Implants

Bioceramics are an important subset of biomaterials, employed in medical and orthopedic applications, mainly for the repair and replacement of diseased and damaged parts of the human skeleton, bone, teeth, and joints. Based on the common response of tissues to implants, bioceramics are classified into three groups: (1) bioinert ceramics, e.g., Al2O3, and ZrO2; (2) bioactive ceramics, e.g., hydroxyapatite (HAp); and (3) bioresorbable ceramics such as b- tricalcium phosphate (b-TCP). With the advent of many bioceramic compositions, it has been the primary focus of this field to ensure the safety of newly developed or currently used materials.

The safety and reliability concerns regarding bioceramics originates from the potential prolonged leaching of ions in the physiological environment, from the integrity of the tissue/implant interface, and from the fatigue fracture and wear behavior of load-bearing implants. HAp, b-TCP, and calcium sulfate hemihydrate and dihydrate have long been recognized as appropriate materials for bones, due to their chemical and biological similarity to human hard tissues. Properly screening bioceramic powders and fabricated implant parts, prior to in vitro and in vivo tests, is appealing in term of safety, and time- and cost-savings.

In this webinar, we will demonstrate how modern analytical tools (Scheme) can be used for full qualification of bioceramic precursors, including following FDA recognized consensus standards (such as ASTM F1088, F1185, F2024, F2224, ISO 13175-3, 13779-2, 13779-3, and USP 232/Q3D).


Please view all of our webinars here.

About the Presenters:

Xinwei Wang

Xinwei Wang, Ph.D., Project Manager
Dr. Xinwei Wang is a materials scientist and chemist with expertise on purity assay and trace elemental analysis of materials and processes involved in advanced technologies, including but not limited to high purity metals, advanced alloys, high performance ceramics, semiconductors, and pharmaceuticals that are essential for aerospace, electronics, medical, petrochemical and energy industries, etc.

Dr. Xinwei Wang joined EAG Laboratories in 2009. He started as an analyst, later became a scientist for trace analysis, with a focus on method development and validation for GDMS, ICP-OES, ICP-MS, IGA, and thermal analysis.

In this webinar we will cover the qualification of bioceramic precursors:

  • From composition to trace level impurities (elements and phases)
  • From macroscopic to microscopic structure
  • From surface to bulk structures
  • From specification/regulatory compliance to investigative analysis
  • Thermal properties pertinent to ceramic sintering